Tele2 AB: Change in the Number of Shares in Tele2

STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Tele2 AB (STO:TEL2B) (STO:TEL2A) (OSE:TLE201) Tele2 AB, (“Tele2”), (NASDAQ OMX Stockholm: TEL2 A and TEL2 B), today announced that Tele2’s total number of shares has increased with 2,300,000 shares. The change refers to an issue of 2,300,000 new class C shares in December

Board Change in Opus Group

STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Opus Group (STO:OPUS) Göran Nordlund, chairman of the board of Opus Group, has informed the nomination committee that he will not stand for re-election at the next AGM. Göran has been involved in the board of Opus Group for 14 years and

SCA: Conversion of Shares

STOCKHOLM, Sweden–(BUSINESS WIRE)–Regulatory News: SCA (Svenska Cellulosa AB) (STO:SCAA) (STO:SCAB) According to SCA’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such

Camurus AB: Braeburn Pharmaceuticals and Camurus Enroll First Patient in a Phase 3 Efficacy Trial of Long-Acting Treatment for Opioid Dependence

PRINCETON, N.J. & LUND, Sweden–(BUSINESS WIRE)–Regulatory News: Braeburn Pharmaceuticals and Camurus  (STO:CAMX) announce that the first patient has been randomized in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent patients. CAM2038 medications are designed for long-acting weekly and monthly administration. This randomized,